Weight Loss Medications Found to Cause Hair Loss Concerns

WHO:

Fast Company - Researchers at the University of Pennsylvania conducted the study.

The Independent - The study involved around 50,000 people, including patients using GLP-1 agonist drugs like Mounjaro, Ozempic, and Wegovy.

WHAT:

Fast Company - A study found that taking GLP-1s correlated with a higher likelihood of hair loss compared to other diabetes treatment options.

Fast Company - GLP-1 users were 37% more likely to develop alopecia than patients taking SGLT-2 inhibitors and 68% more likely than those on DPP-4 inhibitors.

The Independent - The UK Medicines and Healthcare products Regulatory Agency (MHRA) received 399 reports of hair loss related to tirzepatide in 2026 and 541 reports in the previous year. It also received 148 reports linked to semaglutide in 2026 and 164 reports in the previous year.

Fast Company - Of the 12,000 patients taking GLP-1s, approximately 200 developed alopecia, or around 1.6%.

WHERE:

Fast Company - The study was conducted at the University of Pennsylvania.

The Independent - The MHRA is based in the UK.

WHEN:

Fast Company - The study examined patients prescribed GLP-1s between 2019 and 2024.

The Independent - Reports of hair loss were noted for the year 2026 and the previous year.

WHY:

Fast Company - The researchers noted that hair loss may have significant psychosocial consequences, affecting self-esteem, quality of life, and adherence to treatment.

The Independent - The team suggested that weight loss and reduced caloric intake might contribute to hair loss, potentially causing physiological stress and micronutrient deficiencies.

HOW:

Fast Company - The study compared 12,000 Type 2 diabetes patients on GLP-1s with those using other diabetes treatment options.

The Independent - The researchers adjusted for factors such as age and weight when comparing rates of alopecia among different drug users.

(UPDATED July 23, 2026 20:21 UTC)

A new study from researchers at the University of Pennsylvania has found that patients using GLP-1 agonist drugs like Mounjaro, Ozempic, and Wegovy may face a higher likelihood of hair loss compared to those on other diabetes treatments. Specifically, GLP-1 users were 37% more likely to develop alopecia than patients taking SGLT-2 inhibitors and 68% more likely than those on DPP-4 inhibitors, with around 1.6% of the 12,000 patients studied developing the condition. The UK Medicines and Healthcare products Regulatory Agency has received numerous reports of hair loss related to these medications, prompting researchers to suggest that weight loss and reduced caloric intake could contribute to this issue.